Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
1e6 of the anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HP2H3) and negative control protein respectively, PE signals was used to evaluate the binding activity (QC tested).
Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 1 μg/mL (100 μL/well) can bind Anti-SLAMF7/CS1 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).
The purity of Rhesus macaque SLAMF7, His Tag (Cat. No. SL7-R52H7) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Elotuzumab | PDL-063; HuLuc-63; BMS-901608 | Approved | Abbvie Inc, Bristol-Myers Squibb Company | Empliciti | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2015-11-30 | Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Polycythemia Vera; Smoldering Multiple Myeloma; Leukemia, Plasma Cell; Multiple Myeloma; Primary Myelofibrosis; Lymphoma; Thrombocythemia, Essential | Details |
| Elotuzumab | PDL-063; HuLuc-63; BMS-901608 | Approved | Abbvie Inc, Bristol-Myers Squibb Company | Empliciti | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2015-11-30 | Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Polycythemia Vera; Smoldering Multiple Myeloma; Leukemia, Plasma Cell; Multiple Myeloma; Primary Myelofibrosis; Lymphoma; Thrombocythemia, Essential | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital) | Phase 2 Clinical | University Hospital Würzburg | Multiple Myeloma | Details | |
| WS-CART-CS1 | WS-CART-CS1 | Phase 1 Clinical | Washington University School Of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research | Multiple Myeloma | Details |
| MB-104 | MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR | Phase 1 Clinical | City Of Hope National Medical Center | Stomach Neoplasms; Glioblastoma; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms | Details |
| CS1 Targeted CAR T-cells (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) | Clinical | Wuhan BioRaid Biotechnology Co Ltd, Tongji Hospital | Hematologic Neoplasms | Details | |
| SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital) | Phase 2 Clinical | University Hospital Würzburg | Multiple Myeloma | Details | |
| WS-CART-CS1 | WS-CART-CS1 | Phase 1 Clinical | Washington University School Of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research | Multiple Myeloma | Details |
| MB-104 | MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR | Phase 1 Clinical | City Of Hope National Medical Center | Stomach Neoplasms; Glioblastoma; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms | Details |
| CS1 Targeted CAR T-cells (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) | Clinical | Wuhan BioRaid Biotechnology Co Ltd, Tongji Hospital | Hematologic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
